GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ZYDG2   Click here for help

GtoPdb Ligand ID: 13925

Compound class: Synthetic organic
Comment: ZYDG2 is an orally bioavailable free fatty acid receptor 1 (FFAR1; GPR40) agonist [1]. It is proposed for the treatment of type 2 diabetes, through activation of FFAR1 signalling in pancreatic β-cells. ZYDG2 is claimed to be devoid of the liver toxicity (via bile acid transporter inhibition) that led to the termination of fasiglifam clinical development.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 0
Rotatable bonds 20
Topological polar surface area 96
Molecular weight 849.04
XLogP 4.03
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC#C[C@H](CC(=O)O[Ca]OC(=O)C[C@H](C#CC)C1=CC=C(C=C1)OCC2=CC(=CC=C2)CN3CC4CC(C3)O4)C5=CC=C(C=C5)OCC6=CC(=CC=C6)CN7CC8CC(C7)O8
Isomeric SMILES CC#C[C@@H](CC(=O)O[Ca]OC(=O)C[C@@H](C#CC)C1=CC=C(OCC2=CC=CC(CN3CC4CC(C3)O4)=C2)C=C1)C5=CC=C(OCC6=CC(CN7CC8CC(C7)O8)=CC=C6)C=C5
InChI InChI=1S/2C25H27NO4.Ca/c2*1-2-4-21(12-25(27)28)20-7-9-22(10-8-20)29-17-19-6-3-5-18(11-19)14-26-15-23-13-24(16-26)30-23;/h2*3,5-11,21,23-24H,12-17H2,1H3,(H,27,28);/q;;+2/p-2/t2*21-,23?,24?;/m10./s1
InChI Key MIHKALXSIRBOKN-YNYJSAJESA-L

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Jain MR, Giri SR, Trivedi CJ, Bhoi BB, Rath AC, Rathod RM, Sundar R, Bandyopadhyay D, Ramdhave R, Patel GD et al.. (2025)
Discovery of ZYDG2: A potent, selective, and safe GPR40 agonist for treatment of type 2 diabetes.
J Pharmacol Exp Ther, 392 (4): 103534. [PMID:40158321]